Advanced Solid Tumor
18 competing products in clinical development for Advanced Solid Tumor.
Pipeline by Phase
Phase 111
Phase 1/25
Phase 22
All Products (18)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Raludotatug deruxtecan | Daiichi Sankyo | Phase 2 | Recruiting | 42 |
| HER3-DXd | Daiichi Sankyo | Phase 2 | Recruiting | 42 |
| Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo | Phase 1/2 | Recruiting | 39 |
| DS-3939a | Daiichi Sankyo | Phase 1/2 | Recruiting | 39 |
| DS5361b + Pembrolizumab | Daiichi Sankyo | Phase 1 | Recruiting | 36 |
| Valemetostat tosylate + T-DXd + Dato-DXd | Daiichi Sankyo | Phase 1 | Recruiting | 36 |
| KK2269 + Docetaxel | Kyowa Kirin | Phase 1 | Recruiting | 36 |
| DS-1103a + T-DXd | Daiichi Sankyo | Phase 1 | Active | 33 |
| DS-8273a | Daiichi Sankyo | Phase 1 | Completed | 29 |
| DS-3078a | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Milademetan + Milademetan | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Eribulin Mesylate | Eisai | Phase 1 | Completed | 29 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1 | Active | 27 |
| LY3499446 + Abemaciclib + Cetuximab + Erlotinib + Docetaxel | Eli Lilly | Phase 1/2 | Terminated | 24 |
| DS-1471a | Daiichi Sankyo | Phase 1 | Terminated | 21 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1/2 | Terminated | 18 |
| AFM24 + Atezolizumab 840 MG in 14 ML Injection | Affimed | Phase 1/2 | Terminated | 14 |
| BBP-398 | LianBio | Phase 1 | Terminated | 11 |